let ter to the editor, Medford 7 estimated the cost benefi ts of medical thoracoscopy. Although he referred to patients with unexplained pleural effusions, the arguments of a shorter wait period to perform pleurodesis and a shorter hospital stay with TTP compared with talc slurry would favor TTP as the more cost-effective treatment of malignant pleural effusion against indwelling pleural cath eter if patient survival exceeds 6 weeks.
Hospitalization Due to COPD Exacerbation

To the Editor:
I read with interest the editorial of Rabe 1 in CHEST (August 2012), and I want to share his claim on the quality of data sets not only for retrospective cohort studies but also for randomized controlled trials. It has been suggested that admission to hospital for acute exacerbations of COPD (AECOPD) allows the identifi cation of a subgroup of patients with a poorer prognosis. 2 The study of Soler-Cataluña et al 3 confi rmed that severe AECOPD, that is, exacerbation episodes requiring hospital management, exert a direct and independent effect on the survival of patients with COPD. García-Aymerich et al 4 reported a 50% mortality rate at 5 years following at least one COPD hospitalization. Mortality rate after COPD-related admission was 55% at 5 years in a large cohort of Veterans Affairs patients (N 5 51,353). 5 When that rate was compared with other diseases, it was close to oncologic mortality range. The four most common malignancies in developed countries have the following 5-year relative survival rates: 73% to 89% for breast cancer, 50% to 99% for prostate cancer, and about 43% to 63% for colorectal cancer. Only lung cancer, which has the worst survival rate (12-18%), appeared far beyond AECOPD mortality. 6 Does AECOPD hospitalization as a marker of severity constitute one more inexorable and unavoidable feature of COPD natural history? Individual interventional studies may not have enough power to show changes in hospitalization, but if full datasets were provided that would enable systematic analysis, there might be a chance to show a difference.
We could only fi nd hospitalization data in three of the 14 included studies in a systematic review. 7 AECOPD was reported with a wide spectrum of end points in each trial, such as the following: proportion of subjects with at least one exacerbation for all kind of severities; time to fi rst AECOPD; duration of AECOPD; number of subjects treated with systemic corticosteroids, antibiotics, or both; and percentage of subjects with one or more AECOPD.
This issue seems relevant enough to request reporting AECOPD hospitalizations in absolute fi gures. Analyses of databases trying to assess drug safety of COPD drugs, as suggested by Rabe, 1 might include drug effi cacy, too.
